Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of joining the trial
- People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through a tissue or cell sample
- People whose prostate cancer has spread to other parts of the body and is no longer responding to standard hormone-lowering treatment, with testosterone levels kept very low (below 50 ng/dL)
- People who are due to start a specific type of hormone therapy (such as abiraterone acetate or a similar advanced hormonal treatment) within 15 days of joining the trial
- People who are willing and able to attend scheduled trial visits and follow the trial procedures
- People who are not opposed to taking part in the study
- People who are enrolled in the French social security system
Who may not be able to join:
- People with castration-resistant prostate cancer who have already received advanced hormonal therapies (next-generation hormonal therapies) for their metastatic cancer
- People who are under a legal protection order (such as guardianship or similar arrangements)
- People from whom consent (non-opposition) cannot be obtained
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33142499783
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Relative abundance of Akkermansia muciniphila
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.